Why You Don't Need to Cycle CJC-1295 or Tesamorelin (But You Do Ipamorelin)
When people talk about peptide protocols online, they often treat CJC-1295 and ipamorelin as if they are one single compound, and that makes sense on the surface because the two are almost always sold together in the same vial. But combining them for convenience does not mean they work the same way, and that mix-up is where a lot of bad cycling advice comes from. The recommendation to take a month off every few months applies specifically to ipamorelin, not to CJC-1295 or tesamorelin, and understanding why requires looking at how each peptide actually interacts with your pituitary gland.
Your pituitary gland has more than one type of receptor that can trigger growth hormone release, and the two systems involved here are completely separate from each other. Ipamorelin works through what are called ghrelin receptors, while CJC-1295 and tesamorelin work through growth hormone releasing hormone receptors. These are not the same receptors, they do not share the same feedback mechanisms, and they do not respond to long-term stimulation in the same way. Treating them as identical just because they show up in the same vial leads to unnecessary breaks from compounds that do not actually need them.
The ghrelin receptor system is where the real desensitization problem lives, and it is a well-documented biological process. When you continuously stimulate ghrelin receptors, your body responds by pulling those receptors off the surface of the cells so there are fewer of them available to respond to the signal. This is called receptor downregulation, and it is your body's way of protecting itself from being overstimulated by any one signal for too long. The more you run ipamorelin without a break, the fewer functional receptors you have left, and that directly translates to lower growth hormone output over time even though you are still taking the same dose.
Research tracking this in humans over a 16-week period found that growth hormone response had dropped by around 45 percent from where it started by the time week 16 arrived. That is nearly half the original effect disappearing simply because the receptors had been continuously activated without enough recovery time. The encouraging part of that same research was that when subjects stopped for four weeks, their growth hormone response came back to baseline, so the downregulation is not permanent and the receptors do recover with adequate rest. That four-week recovery window is exactly why the standard cycling advice for ipamorelin tends to be three months on followed by one month off.
CJC-1295 and tesamorelin tell a completely different story because of the receptor system they use and because of how their pharmacokinetics actually work in the body. Tesamorelin has a half-life of roughly 30 minutes, so when you inject it once a day the signal it sends to your growth hormone releasing hormone receptors is brief and then it is over. Your receptors then have more than 23 hours to sit in a resting state before the next dose arrives, and that long recovery window appears to prevent the kind of downregulation that happens with the ghrelin system. The receptors are not being kept in a constant state of stimulation the way ghrelin receptors can be with repeated ipamorelin dosing patterns.
Clinical trial data on tesamorelin supports this picture in a meaningful way because it was studied in daily use for 52 consecutive weeks, and IGF-1 levels held steady throughout that entire period without showing a decline. IGF-1 is produced in the liver in response to growth hormone, so it serves as a reliable downstream marker of whether growth hormone output is being maintained over time. The fact that it stayed consistent across a full year of daily dosing suggests that the growth hormone releasing hormone receptor system is not experiencing the same kind of desensitization that the ghrelin receptor system is prone to. That clinical evidence is the reason there is no published support for cycling tesamorelin on its own.
If you are running CJC-1295 and ipamorelin together, you are still cycling because of the ipamorelin and its effect on ghrelin receptors, so the three months on and one month off structure still applies to your overall protocol. But you should understand that the CJC-1295 component is not the reason for that break, and the cycling is not doing anything protective for that particular peptide. It is simply riding along with the necessary rest period that the ipamorelin requires, so when the break ends and you restart, both compounds come back together even though only one of them truly needed the pause.
This distinction matters practically because some people run tesamorelin as a standalone compound rather than pairing it with ipamorelin, and those people have been told to cycle it based on advice that was never really meant for them. If you are using tesamorelin alone and taking monthly breaks because someone on a forum said to, you are interrupting your protocol unnecessarily and losing potential benefit during those off weeks. The cycling advice was generated in the context of combination vials where ipamorelin is present, and it got applied broadly to everything without anyone stopping to ask whether it actually made sense for each individual compound.
Biology does not care about convention or what got lumped together in a vial for marketing purposes, and the ghrelin receptor system and the growth hormone releasing hormone receptor system are going to behave according to their own separate rules regardless of what protocol advice got passed around online. Ipamorelin deserves respect for the receptor downregulation it can cause, and giving it structured breaks is a reasonable and evidence-supported approach to preserving its effectiveness over time. CJC-1295 and tesamorelin deserve the same level of attention, and that attention means not cycling them without a real reason to do so because the current evidence suggests that reason does not exist.
References
- Gusenbauer M, Haddaway NR. Which academic search systems are suitable for systematic reviews or meta-analyses? Evaluating retrieval qualities of Google Scholar, PubMed, and 26 other resources. Res Synth Methods. 2020. Source
- Lindsey WT, Olin BR. PubMed searches: overview and strategies for clinicians. Nutr Clin Pract. 2013. Source
- Pirani C, Camilleri J. Effectiveness of root canal filling materials and techniques for treatment of apical periodontitis: A systematic review. Int Endod J. 2023. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.